1. Show article details.

    BRIEF-Lineage Cell Therapeutics Presents New Opregen Data

    Reuters – 6:19 PM ET 10/14/2019

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS PRESENTS NEW OPREGEN® DATA AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING. * TREATMENT WITH OPREGEN CONTINUES TO BE WELL TOLERATED Source text for Eikon: Further company coverage:

  2. Show article details.

    Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting

    Business Wire – 1:45 PM ET 10/14/2019

    Treatment with OpRegen Continues to be Well Tolerated with Increased Visual Acuity Observed in Cohort 4 Patients Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced positive additional results from an ongoing Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell tr...

  3. Show article details.

    Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting on October 23, 2019

    Business Wire – 8:00 AM ET 10/07/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal Investigator and Director of R&D, will serve as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the Company’s Vision Restoration Program a...

  4. Show article details.

    Lineage Cell Therapeutics to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019

    Business Wire – 8:00 AM ET 09/30/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration, will be presented at the 201...

  5. Show article details.

    Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019

    Business Wire – 8:00 AM ET 09/26/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brandi L. Roberts, Chief Financial Officer, will be presenting at the 2019 Cantor Global Healthcare Conference on October 4th, 2019 at 1:45pm Eastern Time at the InterContinental Barclay Hotel in Grand Ballroom 1 in New York, NY. About Lineage Cel...

  6. Show article details.

    BRIEF-Lineage Cell Therapeutics Provides Update On Renevia Commercialization Plans

    Reuters – 8:42 AM ET 09/25/2019

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS PROVIDES UPDATE ON RENEVIA COMMERCIALIZATION PLANS. * Lineage Cell Therapeutics Inc (LCTX) - SERCADER LTD. ENGAGED TO IDENTIFY EUROPEAN COMMERCIAL PARTNER Source text for Eikon: Further company coverage:

  7. Show article details.

    Lineage Cell Therapeutics Provides Update on Renevia® Commercialization Plans

    Business Wire – 8:00 AM ET 09/25/2019

    Sercader Ltd. Engaged to Identify European Commercial Partner Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, provided an update on its commercialization plans for Renevia®, the Company’s facial aesthetics product, which was recently granted a Conformité Européenne Mark.

  8. Show article details.

    Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019

    Business Wire – 8:00 AM ET 09/23/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the 2019 Cell & Gene Meeting on the Mesa on October 3rd, 2019 at 5:00pm Pacific Time at the Park Hyatt Aviara Resort in the BlueRock Therapeutics Ballroom in Carlsbad, CA. Organized b...

  9. Show article details.

    BRIEF-Lineage Cell Therapeutics Receives CE Mark Approval For Renevia

    Reuters – 7:09 AM ET 09/19/2019

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS RECEIVES CE MARK APPROVAL FOR RENEVIA®. * Lineage Cell Therapeutics Inc (LCTX) - TRIAL MET ITS PRIMARY ENDPOINT OF CHANGE IN HEMIFACIAL VOLUME AT SIX MONTHS. * LINEAGE CELL THERAPEUTICS (LCTX) - BELIEVE IT IS IN BEST INTERESTS OF SHAREHOLDERS TO SEEK EXTERNAL PARTNER TO LAUNCH RENEVIA IN EUROPEAN MARKET Source text for Eikon: Further company coverage:

  10. Show article details.

    Lineage Cell Therapeutics Receives CE Mark Approval for Renevia®

    Business Wire – 7:00 AM ET 09/19/2019

    Comparative clinical trial met its primary endpoint of change in hemifacial volume at six months Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Renevia®, the Company’s facial aesthetics product, has been granted a Conformité Européenne Mark.

  11. Show article details.

    BRIEF-Lineage Cell Therapeutics Conducts Sale Of Shares In OncoCyte Corporation

    Reuters – 9:16 AM ET 09/11/2019

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS CONDUCTS SALE OF SHARES IN ONCOCYTE CORPORATION. * Lineage Cell Therapeutics Inc (LCTX) - PRICING OF SALE OF 4 MILLION SHARES OF COMMON STOCK OF ONCOCYTE CORPORATION AT A PRICE TO BUYERS OF $1.66 PER SHARE Source text for Eikon: Further company coverage:

  12. Show article details.

    Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

    Business Wire – 9:15 AM ET 09/11/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 4,000,000 shares of common stock of OncoCyte Corporation at a price to buyers of $1.66 per share, the closing price as of September 10, 2019. “Our objective is to build Lineage into a premier cell therapy company.

  13. Show article details.

    Lineage Cell Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019

    Business Wire – 8:00 AM ET 09/05/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference on September 9th, 2019 at 11:15am Eastern Time at the Lotte New York Palace Hotel in the Louis Salon in New York, NY. Inte...

  14. Show article details.

    BRIEF-Lineage Cell Receives U.S. Patent For Stem-Cell Based Method Of Treating Spinal Cord Injury

    Reuters – 8:09 AM ET 09/04/2019

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. PATENT FOR METHOD OF TREATING SPINAL CORD INJURY WITH STEM CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS Source text for Eikon: Further company coverage:

  15. Show article details.

    Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells

    Business Wire – 8:00 AM ET 09/04/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 10,286,009, entitled “Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury” covering methods for utilizing pluripotent stem ...

  16. Show article details.

    Lineage Cell Therapeutics Announces Data From Vision Restoration Program Published in Stem Cells and Development Journal

    Business Wire – 8:00 AM ET 09/03/2019

    Paper Featured as the Publication’s Cover Story Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that its paper entitled “Transplantation of Human Embryonic Stem Cell Derived Retinal Tissue in the Subretinal Space of the Cat Eye,”, has been selected for publishing and will be featured on the cover o...

  17. Show article details.

    BRIEF-Lineage Cell Announces Issuance Of U.S. Patent For System For Generating Immunogenic Dendritic Cells

    Reuters – 8:10 AM ET 08/26/2019

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. PATENT FOR SYSTEM FOR GENERATING IMMUNOGENIC DENDRITIC CELLS Source text for Eikon: Further company coverage:

  18. Show article details.

    Lineage Cell Therapeutics Announces Issuance of U.S. Patent for System for Generating Immunogenic Dendritic Cells

    Business Wire – 8:00 AM ET 08/26/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 10,344,262, for a system for production of antigen presenting dendritic cells from human embryonic stem cells.

  19. Show article details.

    Lineage Cell Therapeutics to Ring Opening Bell at the New York Stock Exchange on August 21, 2019

    Business Wire – 8:00 AM ET 08/20/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that members of Lineage's executive leadership team and Board of Directors will ring The Opening Bell® at the New York Stock Exchange on Wednesday, August 21, 2019.

  20. Show article details.

    Lineage Cell Therapeutics Awarded NIH Grant for Innovative Vision Restoration Program

    Business Wire – 8:00 AM ET 08/13/2019

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that it has been awarded a new $670,621 Small Business Innovation Research grant to advance its Vision Restoration Program, the Company’s proprietary and innovative program generating 3-dimensional human retinal tissue derived from pluripotent cells.

Page:

Today's and Upcoming Events

  • Nov
    11

    LCTX to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    08

    LCTX announced Q2 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.